Results 111 to 120 of about 47,011 (239)

Soluble B7‐H6 as a Novel Diagnostic Biomarker for Post‐Hepatitis B Cirrhosis: A Clinical Value Study

Journal of Clinical Laboratory Analysis, Volume 40, Issue 15, August 2026.
This study investigates the potential of soluble B7‐H6 (sB7‐H6) as a novel diagnostic biomarker for post‐hepatitis B cirrhosis. The infographic visually presents the following key points: (1) Liver Disease Progression: Chronic hepatitis B (CHB) progresses to liver cirrhosis (LC), with serum sB7‐H6 levels increasing stepwise as the disease advances. (2)
Kaiyong Chen, Luxuan Yang, Huaiwu Fu, Lei Cao, Zhu Li   +4 more
wiley   +1 more source

Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal. [PDF]

Gut
Lens S, Burton AR, Davies J, Locatelli M, García-López M, Pocurull A, Jeffery-Smith A, Novikov N, Fletcher SP, Forns X, Pérez-Del-Pulgar S, Maini MK.   +11 more
europepmc   +1 more source

The Predictive Value of Tenascin‐C, Neopterin and Pro‐Inflammatory Cytokines (IFN‐γ, TNF‐α, IL‐6) in Alcohol Use Disorder Treatment Response

Addiction Biology, Volume 31, Issue 8, August 2026.
Thirty patients with AUD undergoing detoxification and 31 healthy controls were evaluated. From baseline to day 7, TNC decreased significantly, accompanied by improvements in depression, anxiety and total symptom scores. Neopterin and cytokine levels remained unchanged.
Guleser Akpinar, Gulsen Sener, Enes Faruk Altunkiliç, Emre Yazgec, Alp Batuhan Ozturk, Nuri Mehmet Basan, Huseyin Aycan Ozsemerci   +6 more
wiley   +1 more source

Hepatitis B Virus Reactivation Risk With IL-17, IL-23/IL-12, or JAK Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Liver Int
Alhalabi M, Alshiekh HA.
europepmc   +1 more source

Expression of HBsAg and HBsAg in liver tissue, correlation with disease activity

, 2011
The pattems of Hepatitis B surface antigen (HBsAg) and Hepatitis B core antigen (HBcAg) expression were studied in liver biopsies taken from 41 patients with chronic HBV disease. Immunohistochemical methods were used on deparaffinized sections for the identification of HBsAg and HBcAg in liver tissue. lkenty-one of the 41 cases (5 1.2%) were classified
Nakopoulou, Lydia, Adraskelas, N., Stefanak, K., Zacharoulis, D., Hadziyanni, St.   +4 more
openaire   +1 more source

Short Inter‐Treatment Interval Treatment With Artificial Liver Support System Reduces 90‐Day Transplant‐Free Mortality in Patients With Hepatitis B Virus–Related Acute‐On‐Chronic Liver Failure: A Retrospective Observational Study

Artificial Organs, Volume 50, Issue 8, Page 1145-1152, August 2026.
ALSS short inter‐treatment interval treatment (patients received two ALSS treatments within 48 h) correlates with improved liver function and 90‐day transplant‐free survival of HBV‐ACLF. This result provides a certain theoretical basis for the timing and time interval of ALSS for HBV‐ACLF, enriches the models and contents of ALSS treatment for HBV‐ACLF,
Jingjie Fu, Fang Chen, Wenfeng Yang, Ting Chen, Jian Xu   +4 more
wiley   +1 more source

Seroprevalence of hepatitis B Surface antigen among apparently healthy primary school pupils inBatagarawa Local Government area of Katsina State, Nigeria

Nigerian Journal of Paediatrics
Introduction: Hepatitis B virus infection is a major public health problem worldwide. It is more infectious and more in Nigeria than the Human Immunodeficiency Virus (HIV).
Habibu B, Belonwu R, Ibrahim M
doaj  

Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection. [PDF]

J Viral Hepat
Drysdale M, Chang R, Wang S, Coutinho A, Gielen V, Man T, Song R, Duh MS, Khalili M, Theodore D.   +9 more
europepmc   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 517-526, August 2026.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

ENPP1 and IFIT2 in PBMCs as early predictive biomarkers for HBsAg clearance and responses to Peg-IFN-α in HBeAg-negative chronic hepatitis B patients. [PDF]

Front Immunol
Pang H, Fu X, Jiang J, Qin B.
europepmc   +1 more source